
TRENDS IN VOLUMES OF ADULT AND PAEDIATRIC ARV FORMULATIONS IN LMICS. PRELIMINARY ANALYSIS FROM THE GPRM DATA

Boniface Dongmo-Nguimfack

WHO/HIV/SIP


Denominator used for calculation: Years and number of patient-years

Years	2011	2012	2013	2014	2015
Thousands API Years	16,970	22,391	28,761	29,287	27,074
Thousands Patient Years	5,657	7,464	9,587	9,762	9,025


Data included

- CHAI/UNITAID:
 - Data included up to 09.2014
- GFATM
 - PQR data included up to 31.12.2015 – but 2015 not complete given reporting delays in PQR
- SCMS
 - Data included up to 31.12.2015
- Rest of PEPFAR
 - Data included up to 12.2013
- UNICEF
 - Data included up to 31.12.2015
- IDA:
 - Data included up to 31.12.2015
- MISSIONPHARMA
 - Data included up to 04.2015
- WHOCPS
 - Data included up to 31.12.2015


Market share (% of total volume in PYR of nucleoside reverse transcriptase inhibitors, excluding FTC and 3TC)




Market share (% of total volume in PYR of 3TC and FTC)




Market share (% of total volume in PYR of EFV, NVP and ETV)




Market share (% of total volume in PYR of protease inhibitors, excluding ritonavir)



Relative uptake of tenofovir containing formulations



Relative uptake of zidovudine containing formulations



FORECASTING DEMAND FOR ARVS

-


**TRENDS OF PEDIATRIC FORMULATIONS UPTAKE
FROM THE GPRM DATABASE**




Denominator used for calculation: Years and Number of Patient Years

	2011	2012	2013	2014	2015
Thousands API Years	1,119	981	1,513	1,329	552
Thousands Patient Years	373	327	504	443	184

Market share (%) of nucleoside reverse transcriptase inhibitors (excluding 3TC and FTC)




Relative uptake of abacavir containing formulations



	2011	2012	2013	2014	2015
ABC + 3TC+ZDV(60+30+60)mg		0%	0%	0%	0%
ABC+3TC(60+30)mg	76%	92%	75%	69%	45%
ABC 20mg/ml	22%	6%	22%	30%	55%
ABC 60mg	2%	2%	2%	1%	0%


■ ABC 60mg
 ■ ABC 20mg/ml
 ■ ABC+3TC(60+30)mg
 ■ ABC + 3TC+ZDV(60+30+60)mg



	2011	2012	2013	2014	2015
ABC 60mg	641	831	1,357	1,095	226
ABC 20mg/ml	7,003	3,362	12,756	38,547	37,167
ABC+3TC(60+30)mg	24,046	50,452	42,607	89,795	30,202
ABC + 3TC+ZDV(60+30+60)mg	0	0	25	0	0


— ABC 60mg
 — ABC 20mg/ml
 — ABC+3TC(60+30)mg
 — ABC + 3TC+ZDV(60+30+60)mg

Relative uptake of didanosine formulations



	2011	2012	2013	2014	2015
ddi 100 mg	9%	39%	12%	69%	92%
ddi 125 mg	68%	41%	22%	0%	0%
ddi 50 mg	7%	0%	0%	0%	0%
ddi 25 mg	16%	21%	66%	31%	8%

■ ddi 25 mg ■ ddi 50 mg ■ ddi 125 mg ■ ddi 100 mg




	2011	2012	2013	2014	2015
ddi 25 mg	287	150	409	191	49
ddi 50 mg	128	0	0	0	0
ddi 125 mg	1,184	298	135	0	0
ddi 100 mg	151	283	72	435	576

— ddi 25 mg — ddi 50 mg — ddi 125 mg — ddi 100 mg




Relative uptake of different zidovudine containing formulations



	2011	2012	2013	2014	2015
3TC+NVP+ZDV(30+50+60)mg	75%	71%	85%	79%	73%
3TC+ ZDV(30+60) mg	16%	21%	9%	18%	16%
ZDV 100mg	5%	2%	4%	1%	5%
ZDV 10mg/ml	5%	6%	2%	2%	5%

■ ZDV 10mg/ml ■ ZDV 100mg ■ 3TC+ ZDV(30+60) mg ■ 3TC+NVP+ZDV(30+50+60)mg



	2011	2012	2013	2014	2015
ZDV 10mg/ml	9,417	11,451	8,028	4,697	3,975
ZDV 100mg	9,452	3,665	13,035	4,167	3,831
3TC+ ZDV(30+60) mg	32,030	38,656	33,696	51,092	11,629
3TC+NVP+ZDV(30+50+60)mg	150,096	131,889	301,841	228,249	53,698


— ZDV 10mg/ml

— ZDV 100mg

— 3TC+ ZDV(30+60) mg


— 3TC+NVP+ZDV(30+50+60)mg

Relative uptake of stavudine containing formulations



	2011	2012	2013	2014	2015
3TC+NVP+D4T (30+50+6)mg	40%	36%	36%	8%	100%
3TC+NVP+D4T (60+100+12)mg	35%	46%	46%	0%	0%
3TC+D4T (30+6) mg	6%	10%	10%	89%	0%
3TC+D4T (60+12) mg	11%	5%	7%	0%	0%
d4T 20 mg	2%	1%	1%	2%	0%
d4T 15 mg	3%	0%	0%	0%	0%
d4T 1 mg/ml	3%	2%	1%	0%	0%


- d4T 1 mg/ml
- d4T 15 mg
- d4T 20 mg
- 3TC+D4T (60+12) mg
- 3TC+D4T (30+6) mg
- 3TC+NVP+D4T (60+100+12)mg
- 3TC+NVP+D4T (30+50+6)mg



	2011	2012	2013	2014	2015
d4T 1 mg/ml	2,693	1,317	270	0	0
d4T 15 mg	2,507	149	60	0	0
d4T 20 mg	1,746	365	147	28	0
3TC+D4T (60+12) mg	10,689	3,644	2,043	0	0
3TC+D4T (30+6) mg	5,576	6,913	2,928	1,088	0
3TC+NVP+D4T (60+100+12)mg	33,943	31,810	13,399	0	0
3TC+NVP+D4T (30+50+6)mg	38,862	24,694	10,383	102	55


- d4T 1 mg/ml
- d4T 15 mg
- d4T 20 mg
- 3TC+D4T (60+12) mg
- 3TC+D4T (30+6) mg
- 3TC+NVP+D4T (60+100+12)mg
- 3TC+NVP+D4T (30+50+6)mg

Relative uptake of different lopinavir formulations



	2011	2012	2013	2014	2015
LPV+RTV (100+25) mg	46%	46%	46%	30%	18%
LPV+RTV(80+20/ml) mg	54%	54%	54%	70%	82%


■ LPV+RTV(80+20/ml) mg ■ LPV+RTV (100+25) mg



	2011	2012	2013	2014	2015
LPV+RTV(80+20/ml) mg	10,539	12,317	17,263	61,686	78,802
LPV+RTV (100+25) mg	8,910	10,564	14,938	26,106	17,122




Relative market share of non-nucleoside reverse transcriptase inhibitors plus LPV



	2011	2012	2013	2014	2015
■ LPV	4%	6%	5%	18%	34%
■ EFV	28%	28%	36%	28%	39%
■ NVP	68%	66%	59%	54%	26%

■ NVP ■ EFV ■ LPV



	2011	2012	2013	2014	2015
■ NVP	316,487	245,806	378,357	265,099	73,667
■ EFV	129,324	103,061	228,566	138,424	110,140
■ LPV	19,449	22,881	32,201	87,792	95,924



Thank you